Abstract
Objective To investigate the value for the clinical application of urokinase combined with Sodi- um Tanshion IIA in the treatment of cerebral thrombosis. Methods 160 cases with cerebral thrombosis in our hospital were chosen. They were randomly divided into A group with 80 cases and B group with 80 cases. A group was the observation group（Tanshion IIA Urokinase combined treatment group）, B group was the control group （urine kinase treatment group）. 2 weeks treatment was a course. The efficacy of treatment in the two groups at the end was taken for statistical analysis. Results The neurological deficits were significantly improved in A and B group before and after treatment（ P 〈 0.05, there was statistically significant）. The neurological deficit scores in A group after treatment was significantly lower than group B （P 〈 0.05, there was statistically significant）. The total effective rate was 95% by the treatment of urokinase and Tanshion IIA in A group which was higher than group B （ P 〈 0.05, there was statistically significant difference）. Conclusion The treatment of urokinase combined with Sodium Tanshion IIA could improve neurological deficits and improve the clinical therapeutic effect. Key words: Intracranial thrombosis ; Urinary plasminogen activator ; Tanshinone
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
